20.500.12556/RUL-139493 Mehanizem delovanja mukoznih cepiv in možnosti uporabe v boju proti SARS-CoV-2 Mechanisms of mucosal vaccines and possibilities of use in the fight against SARS-CoV-2 Večina povzročiteljev nalezljivih bolezni vstopa v telo na površinah sluznic, zato je ta opremljena z mukoznim imunskim sistemom, ki služi kot prva obrambna linija proti patogenom. Zaščitne imunske odzive sluznice lahko sprožimo z imunizacijo sluznice, zato se vse bolj spodbuja razvoj mukoznih cepiv kot alternativa trenutno prevladujočim intramuskularnim cepivom. Mukozni imunski sistem je del prirojenega imunskega sistema, vendar tvori povezavo tudi s pridobljenim imunskim sistemom. Kljub številnim prednostim, se pojavljajo izzivi pri razvoju varnih, stabilnih in ustrezno formuliranih mukoznih cepiv. Preučujejo se različne možnosti dostavnih sistemov in dozirnih oblik za njihovo čim bolj optimalno delovanje. Najpogosteje se za apliciranje mukoznih cepiv uporablja nazalna pot, zato so trenutno najbolj preučevana nazalna cepiva. Na trgu sta dve učinkoviti licencirani nazalni cepivi proti virusu gripe, in sicer FluMist® in Nasovac®. Nazalna cepiva imajo velik potencial tudi v boju proti virusu SARS-CoV-2, vendar je večina tovrstnih cepiv še v zgodnji fazi kliničnih preizkušanj. Most infectious agents enter the body on the surfaces of mucous membranes, which are equipped with a mucosal immune system that serves as the first line of defence against pathogens. Protective mucosal immune responses can be triggered by mucosal immunisation, which is why the development of mucosal vaccines is increasingly being promoted as an alternative to the currently prevalent intramuscular vaccines. The mucosal immune system is part of the innate immune system, but it also forms a link with the acquired immune system, so mucosal vaccines could achieve dual protection. Despite the many advantages, there are challenges in developing safe, stable and appropriately formulated mucosal vaccines. Different options for delivery systems and dosage forms are being explored to optimise their performance. The nasal route is the most commonly used route for the administration of mucosal vaccines, and nasal vaccines are therefore currently the most studied. There are two effective licensed nasal influenza virus vaccines on the market, FluMist® and Nasovac®. Nasal vaccines also have great potential in the fight against SARS-CoV-2, but most of these vaccines are still in the early stages of clinical trials. mukozna cepiva nazalna cepiva SARS-CoV-2 mucosal vaccines nasal vaccines SARS-CoV-2 true false false Slovenski jezik Angleški jezik Diplomsko delo/naloga 2022-09-03 07:17:32 2022-09-03 07:17:36 2022-10-10 15:20:38 0000-00-00 00:00:00 2022 0 0 0000-00-00 NiDoloceno NiDoloceno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 208460 124987907 24512.pdf 24512.pdf 1 78E0AB534A50CBCD8E30FDB0B89486FE ee54cc27a5fd1688bb2a67573dfe1224e2431f23b508c0b615aca61ee076606c ae37a021-2b47-11ed-92af-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=160064 Biotehniška fakulteta 0 0 0